• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

    5/13/25 4:05:00 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARTV alert in real time by email

    64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL

    Median duration of response for AlloNK + rituximab not yet reached and is at least 19.4 months, in line with approved auto-CAR-T therapies in aggressive B-NHL

    AlloNK's activity and well-tolerated safety profile in aggressive B-NHL patients support the potential to deliver deep B-cell depletion in a refractory autoimmune population in outpatient community settings

    SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced new longer-term Phase 1/2 data demonstrating durable responses for AlloNK® (also known as AB-101) in combination with rituximab (RTX) in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) at the American Society of Gene & Cell Therapy (ASGCT) 28th annual meeting.

    "We are thrilled to see continuing durability, now with an ongoing median duration of response of at least 19 months. These data are maturing as one of the data sets with the highest activity and durability for any allogeneic cell therapy in heavily pretreated, aggressive B-NHL patients and in line with approved auto-CAR-T therapies," said Fred Aslan, M.D., Chief Executive Officer of Artiva. "AlloNK has now demonstrated its ability to significantly enhance the activity of both anti-CD20 rituximab and Affimed's CD30-directed NK cell engager AFM13 in late line, cancer populations. These findings reinforce the potential of AlloNK to drive deep and durable responses in autoimmune diseases through the enhancement of standard of care monoclonal antibodies and robust B-cell depletion." 

    David G. Maloney, M.D., Ph.D., Professor Emeritus of Translational Science and Therapeutics at the Fred Hutch Cancer Center added, "I had the opportunity to dose the first patient with rituximab in 1997 and have most recently adopted the clinical use of autologous CAR-T cell therapies. It is encouraging to see AlloNK demonstrate robust responses and meaningful durability in tough to treat late-line patients with aggressive NHL that are comparable to those with autologous CAR-T cell therapies. The available B-NHL data of AlloNK in combination with rituximab supports readthrough of AlloNK's mechanism of action from treatment of aggressive B-NHL to treatment of autoimmune diseases."

    Key highlights supporting AlloNK + RTX as a promising cellular therapy for a heavily pretreated CD20 positive R/R B-NHL patient population include:

    • High Response Rates – 64% complete response (CR) rate (9/14) for AlloNK + RTX with patients who were naïve to prior CAR-T cell therapy
      • Patients received a median three prior lines and 13 out of 14 patients had aggressive B-NHL
      • Comparable to outcomes with approved auto-CAR-T cell therapies in a similar heavily pretreated, later line patient population with aggressive B-NHL, which in registrational studies showed a 58% CR rate with Yescarta (axicabtagene ciloleucel, ZUMA-1 trial), 53% CR rate with Breyanzi (lisocabtagene maraleucel, TRANSCEND NHL 001 trial), and 40% CR rate with Kymriah (tisagenlecleucel, JULIET trial)
    • Prolonged Durability Beyond 12 Months – Median duration of response (mDoR) not yet reached and is at least 19.4 months as of the March 7, 2025, data-cut in patients following treatment with AlloNK + RTX
      • Complete responses sustained in the majority of patients treated with AlloNK + RTX
      • Comparable to outcomes with approved auto-CAR-T cell therapies in a similar heavily pretreated, later line patient population with aggressive B-NHL, which in registrational studies showed an 11.1 month mDoR with Yescarta (axicabtagene ciloleucel, ZUMA-1 trial), 23.1 month mDOR with Breyanzi (lisocabtagene maraleucel, TRANSCEND NHL 001 trial), and mDOR not reached at 40.3 months follow up with Kymriah (tisagenlecleucel, JULIET trial) 
    • Well-tolerated Safety Profile – AlloNK + RTX was well-tolerated among the 45 patients dosed
      • All cytokine release syndrome (CRS) events were re-classified as infusion-related reactions (IRRs) based on: analysis of cytokines of the 3 patients with reported low-grade CRS, demonstrating an absence of elevated IL-6 and other cytokines; timing of reported events, all occurring within 24 hours of cell infusion; and resolution of symptoms without specialized treatment. These re-classifications support AlloNK's potentially well-tolerated profile, suitable for outpatient community administration
      • No immune effector cell associated neurotoxicity syndrome (ICANS), no graft-versus-host disease, no deaths related to AlloNK, and no trial discontinuations due to AlloNK related adverse events have been reported to date
      • In line with the usage of lymphodepletion regimens, the most common treatment-emergent adverse events (TEAEs) were hematologic, including neutropenia (84%), leukopenia (82%), and lymphopenia (71%). IRRs and febrile neutropenia (n=3; 7% each) were the only related serious TEAEs reported in more than 1 patient
    • Implications for the Treatment of Autoimmune Disease
      • AlloNK Drives Potent and Durable B-Cell Depletion – Deep B-cell depletion and prolonged duration of response for over 19 months in heavily pretreated R/R B-NHL patients supports a potent mechanism of action with potential to deliver deep B-cell depletion in a refractory autoimmune population
      • AlloNK has a Tolerability Profile Compatible with Use in a Community Setting – Lack of cell-therapy driven acute toxicities like CRS and ICANS in heavily pretreated patients with aggressive disease, including older patients, supports the potential for outpatient administration

    About Artiva Biotherapeutics

    Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva's lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases. This includes two company sponsored trials, one in systemic lupus erythematosus for patients with or without lupus nephritis, and a basket trial across autoimmune diseases including rheumatoid arthritis and Sjögren's disease, as well as an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva's pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell's NK cell manufacturing technology and programs. 

    Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva Biotherapeutics, Inc. (the "Company") regarding the potential benefits, accessibility, effectiveness and safety of AlloNK; the Company's belief that the longer-term Phase 1/2 data supports a mechanism of action with potential to deliver responses in autoimmune disease; the potential for outpatient administration; and the Company's ability to advance AlloNK in autoimmune disease. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company's actual results to differ from current expectations are discussed in the Company's filings with the Securities and Exchange Commission (the "SEC"), including the section titled "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contacts

    Investors: Neha Krishnamohan, Artiva Biotherapeutics, [email protected]

    Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., [email protected], +1.858.344.8091

    Source: Artiva Biotherapeutics, Inc.



    Primary Logo

    Get the next $ARTV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARTV

    DatePrice TargetRatingAnalyst
    12/30/2024$20.00Buy
    H.C. Wainwright
    8/13/2024$21.00Buy
    Jefferies
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    8/13/2024Buy
    TD Cowen
    8/13/2024$18.00Outperform
    Wedbush
    8/13/2024$23.00Buy
    Needham
    More analyst ratings

    $ARTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

      SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      11/14/24 4:56:18 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Artiva Biotherapeutics Inc.

      SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      9/3/24 4:18:05 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

      SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      8/1/24 7:00:07 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:27:11 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner 5am Partners Vi, Llc converted options into 1,058,284 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $9,999,996 worth of shares (833,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:15:09 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Venbio Global Strategic Fund Iii, L.P. bought $4,999,992 worth of shares (416,666 units at $12.00), converted options into 1,058,284 shares and acquired 461,687 shares (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/22/24 8:26:49 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Artiva Biotherapeutics Inc.

      SCHEDULE 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      5/15/25 4:44:26 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Artiva Biotherapeutics Inc.

      10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      5/8/25 8:06:33 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      5/8/25 8:03:54 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

      IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

      5/8/25 8:00:00 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

      SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

      4/8/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

      SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph

      1/29/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

      SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. EDT. Members of the Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the "Investor

      5/28/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

      64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL Median duration of response for AlloNK + rituximab not yet reached and is at least 19.4 months, in line with approved auto-CAR-T therapies in aggressive B-NHL AlloNK's activity and well-tolerated safety profile in aggressive B-NHL patients support the potential to deliver deep B-cell depletion in a refractory autoimmune population in outpatient community settings SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose

      5/13/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

      IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

      5/8/25 8:00:00 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

      12/30/24 7:13:58 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

      Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

      8/13/24 7:24:03 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Artiva Biotherapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Artiva Biotherapeutics with a rating of Overweight and set a new price target of $23.00

      8/13/24 7:23:42 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Banerjee Subhashis was granted 50,000 shares (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      4/25/25 5:07:02 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Banerjee Subhashis

      3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      4/25/25 5:03:53 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Aslan Fred was granted 200,000 shares, increasing direct ownership by 92% to 416,665 units (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      3/7/25 4:35:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care